Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03164486 · ClinicalTrials.gov registry record · Early Phase 1

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

A Early Phase 1 study of Breast Carcinoma and Colorectal Carcinoma, sponsored by Julie L. Sutcliffe, Ph.D.

Active
Registry status
Early Phase 1
Development phase
27
Enrollment target
1
Study location

NCT03164486: Active Early Phase 1 study of Breast Carcinoma and Colorectal Carcinoma, sponsored by Julie L. Sutcliffe, Ph.D.

NCT03164486 is a Early Phase 1 study of Breast Carcinoma and Colorectal Carcinoma that is active but no longer recruiting, run by Julie L. Sutcliffe, Ph.D. The registered enrollment target is 27 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03164486, a Early Phase 1 study of Breast Carcinoma and Colorectal Carcinoma, is active but no longer recruiting, sponsored by Julie L. Sutcliffe, Ph.D.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Primary Outcome

Assessed by measures and/or changes in a given vital sign

Interventions

  • DRUG 18F-αvβ6-BP

Study Locations (1)

California

  • University of California Davis Comprehensive Cancer Center - Sacramento

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2016-11
Est. Completion 2026-12
Phase Early Phase 1
Julie L. Sutcliffe, Ph.D

1 total trials

What the registry record for NCT03164486 still lists

NCT03164486 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (96% lower).

The record links to 8 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which 18F-αvβ6-BP is the first listed.

NCT03164486 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03164486 about?

NCT03164486 is a clinical study titled "First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide". This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate ca...

What is the current status of trial NCT03164486?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2016-11. Estimated completion is 2026-12.

What conditions does trial NCT03164486 study?

This clinical trial studies the following conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Pancreatic Carcinoma, Metastatic Malignant Neoplasm in the Lung.

What interventions are being tested in trial NCT03164486?

The interventions under investigation include: 18F-αvβ6-BP (DRUG).

Who is sponsoring clinical trial NCT03164486?

This trial is sponsored by Julie L. Sutcliffe, Ph.D, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03164486 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03164486's enrollment target sits among peer trials

27 94th of 106 higher than 11 of 106 other Breast Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03164486, the US trial registry maintained by the National Library of Medicine. NCT03164486 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.